- Conditions
- Advanced Solid Tumors
- Interventions
- Talazoparib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Alhambra, California • Bakersfield, California • Fullerton, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 1,113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
- Drug · Other · Radiation + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
- Conditions
- Contact Lens Complication, Contact Lens Acute Red Eye, Contact Lens Related Corneal Infiltrate (Disorder), Contact Lens-Induced Corneal Fluorescein Staining
- Interventions
- No intervention
- Other
- Lead sponsor
- Southern California College of Optometry at Marshall B. Ketchum University
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 171 participants
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Fullerton, California • Fort Lauderdale, Florida • Columbus, Ohio + 1 more
- Conditions
- Intermittent Exotropia
- Interventions
- Overminus treatment, Non-overminus treatment
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Fullerton, California • Rochester, Minnesota
- Conditions
- Light Chain Deposition Disease, Smoldering Multiple Myeloma
- Interventions
- Clinical Observation, Lenalidomide, Quality-of-Life Assessment
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 601
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Rabeprazole sodium, Esomeprazole
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 85
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Discussion, Medical Chart Review, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 15 Years to 39 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 480
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 302 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- pimavanserin tartrate, placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 62
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 58 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab, methotrexate, 23-Valent Pneumococcal Polysaccharide Vaccine, Tetanus Toxoid Adsorbed Vaccine
- Biological · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 47
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 42 more
- Conditions
- Advanced Solid Tumor, Colorectal Cancer
- Interventions
- TORL-3-600
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Fullerton, California • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- Breast Cancer
- Interventions
- Raloxifene, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 19,747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 492
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
- Conditions
- Glioblastoma, Adult-type Diffuse Gliomas
- Interventions
- Pemigatinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Duarte, California • Fullerton, California + 28 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
- Conditions
- Alzheimer Disease, Cognition Disorders
- Interventions
- florbetapir F 18 PET scan
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 75
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more
- Conditions
- Atrial Flutter
- Interventions
- Blazer® Open-Irrigated Ablation Catheter, Control Catheter
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fullerton, California • Sacramento, California + 21 more
- Conditions
- Walking Impairment, Multiple Sclerosis
- Interventions
- ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo
- Drug · Other
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 558 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 78
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 950
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
- Conditions
- Muscle Hypertrophy, Healthy and Well-Trained Men and Women
- Interventions
- Time Restricted Eating, Normal Feeding, Resistance Training, Whey Protein
- Other · Dietary Supplement
- Lead sponsor
- California State University, Fullerton
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Multiple Sclerosis
- Interventions
- BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fullerton, California + 35 more
- Conditions
- Sepsis
- Interventions
- Drotrecogin alfa (activated)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 152
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 149 more
- Conditions
- Gaucher Disease, Type 1
- Interventions
- velaglucerase alfa
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 3 Years and older
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 28 more